Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Work In Process (2025)

Crinetics Pharmaceuticals has reported Work In Process over the past 1 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Work In Process at $2.0 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $2.0 million (changed N/A YoY), and the annual figure for FY2025 was $2.0 million, changed.
  • Work In Process for Q4 2025 was $2.0 million at Crinetics Pharmaceuticals.
  • Over the last five years, Work In Process for CRNX hit a ceiling of $2.0 million in Q4 2025 and a floor of $2.0 million in Q4 2025.